Here's What I'm Planning With My Eli Lilly Position
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 20 Oct 2026, 14:45 UTC
- Recorded by Tahlil Plus
- 20 Oct 2026, 20:06 UTC
AI-generated source summary
Eli Lilly's business is booming due to its weight loss treatments, with a recently developed pill version gaining significant adoption. The company's revenue has seen exponential growth, more than doubling in just a couple of years. Looking back over a decade, the acceleration in revenue has been significant, reaching $79.67 billion. Both revenue and operating margins (currently at 49.72%) are increasing, indicating strong profitability and efficient operations. Return on invested capital has also seen a substantial rise since 2020, reaching 37.27%, suggesting effective R&D investments. While facing potential headwinds from US administration policies that may push for lower prices, the company's strong R&D pipeline and consistent improvement in financial metrics like revenue and return on invested capital make its valuation of 26.44 (forward P/E) attractive. The intrinsic value is estimated at $1523.01, presenting an approximate 21.88% upside from the current market price of $1251.81.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.